Christine zu Eulenburg

1 presentation

• T26. A PHASE 2 CLINICAL TRIAL EXPLORING EFFICACY AND SAFETY OF THE VASOPRESSIN V1B ANTAGONIST BH-200, A TREATMENT FOR MDD, EVALUATING THE PERFORMANCE OF A GENETIC CLASSIFICATION TOOL TO IDENTIFY A SUBSET OF PATIENTS WITH LARGER IMPROVEMENT

  2026 ASCP Annual Meeting